化合物Encorafenib T6487
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
500 mg | 1269440-17-6 | ¥9,950.00 | 询底价 |
10 mg | 1269440-17-6 | ¥1,263.00 | 询底价 |
100 mg | 1269440-17-6 | ¥4,430.00 | 询底价 |
5 mg | 1269440-17-6 | ¥756.00 | 询底价 |
50 mg | 1269440-17-6 | ¥3,798.00 | 询底价 |
1 mL | 1269440-17-6 | ¥832.00 | 询底价 |
1 mg | 1269440-17-6 | ¥291.00 | 询底价 |
25 mg | 1269440-17-6 | ¥1,940.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Encorafenib
描述: Encorafenib (LGX818) 是一种可口服的突变型 BRaf V600E 抑制剂,IC50为 0.3 nM,具有潜在的抗肿瘤活性。
细胞实验: LGX818 is dissolved in DMSO. A375 is a melanoma cell line that harbors the B-Raf V600E mutation. A375-luc cells engineered to express luciferase is plated to 384-well white clear bottom plates as 1,500 cells/50 μL/well in DMEM containing 10% FBS. Test compounds, dissolved in 100% DMSO at appropriate concentrations, are transferred to the cells by a robotic Pin Tool (100 mL). The cells are incubated for 2 days at 25°C, then 25 μL of BrightGloTM is added to each well and the plates are read by luminescence. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software. wild type and V600E B-Raf.
激酶实验: The Raf kinase activity reaction is started by the addition of 10 μL per well of 2×ATP diluted in assay buffer. After 3 hours (bRaf(V600E)) or 1 hour (c-Raf), the reactions are stopped with the addition of 10 μL of stop reagent (60 mM EDTA). Phosphorylated product is measured using a rabbit anti-p-MEK antibody and the Alpha Screen IgG (ProteinA) detection Kit, by the addition of 30 μL to the well of a mixture of the antibody (1:2000 dilution) and detection beads (1:2000 dilution of both beads) in bead buffer (50 mM Tris, pH 7.5, 0.01% Tween20). The additions are carried out under dark conditions to protect the detection beads from light. A lid is placed on top of the plate and incubated for 1 hour at room temperature, then the luminescence is read on a PerkinElmer Envision instrument. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software
体外活性: In the A375 (BRAFV600E) human melanoma cell line LGX818 suppresses phospho-ERK (EC50 = 3 nM) leading to potent inhibition of proliferation (EC50 = 4 nM). No significant activity is observed against a panel of 100 kinases (IC50 > 900 nM) and LGX818 does not inhibit proliferation of > 400 cell lines expressing wild-type BRAF. Contributing to the high potency of LGX818 is the extremely slow off-rate from BRAFV600E which is not observed with other RAF inhibitors. In biochemical assays the dissociation half-life is >24 hours which translated into sustained target inhibition in cells following drug wash-out. [1]
体内活性: LGX818 treatment at oral doses as low as 6 mg/kg resulted in strong (75%) and sustained (>24 hours) decrease in phospho-MEK, even following clearance of drug from circulation in single dose PK/PD studies in human melanoma xenograft models (BRAFV600E). LGX818 induces tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1 mg/kg. Consistent with the in vitro data, LGX818 is inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid, with good tolerability and linear increase in exposure. Efficacy is also achieved in a more disease-relevant spontaneous metastatic melanoma and a model of melanoma brain metastasis. LGX818 is a potent and selective RAF kinase inhibitor with unique biochemical properties that contribute to an excellent pharmacological profile. [1]
存储条件: keep away from direct sunlightPowder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 93 mg/mL (172.2 mM)
5% DMSO+95% Saline : 4.65 mg/mL (8.61 mM, suspension)
DMSO : 45 mg/mL (83.33 mM)
关键字: inhibit | LGX 818 | Raf kinases | Raf | LGX-818 | Encorafenib | Inhibitor
相关产品: Vemurafenib | Regorafénib N-oxyde (M2) | RAF265 | PROTAC B-Raf degrader 1 | Lifirafenib | BMS-214662 | Effusanin A | Ro 5126766 | Cyclorasin 9A5 | Zabofloxacin hydrochloride
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library | Anti-Pancreatic Cancer Compound Library
化合物Encorafenib T6487信息由TargetMol中国为您提供,如您想了解更多关于化合物Encorafenib T6487报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途